New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:31 EDTNBSNeoStem announces access to new $30M equity facility
NeoStem announced that it has filed today with the U.S. Securities and Exchange Commission a prospectus supplement to its shelf registration statement enabling it to access its new equity facility with Aspire Capital Fund which replaced the prior agreement under which the company received the full $20M in equity funding. Under the new agreement, NeoStem has the right to sell up to $30M in shares of common stock to Aspire Capital subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the company with additional capital and flexibility. As of the March 31, the company had approximately $41M of cash and cash equivalents available to fund operations.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
07:40 EDTNBSNeoStem announces extension of study under grant from CIRM
NeoStem announced the extension of its study under a 2014 Early Translational grant from the California Institute of Regenerative Medicine, or CIRM, for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa. Under the $4M grant made to the University of California, Irvine, NeoStem is entitled, through a subaward, to $1M of new funds adding to the original $0.5M awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
April 7, 2015
10:38 EDTNBSNeoStem management to meet with Philadelphia Securities Association
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use